Skip to content

An "off-on" fluorescent aptasensor based on FRET and magnetic beads for detection of circulating tumor cells in lung cancer.

Aug 2026 · Analytical Methods · Vol 18, pp. 7628-7636 · 0 citations · 35 references
Medicine

TL;DR

A novel "off-on" fluorescent aptasensor based on fluorescence resonance energy transfer (FRET) and streptavidin-modified magnetic beads (MBs) for the sensitive and specific detection of A549 CTCs in lung cancer.

Abstract

Circulating tumor cells (CTCs) serve as critical biomarkers for early diagnosis, prognosis monitoring, and treatment response evaluation in lung cancer. Herein, we report a novel "off-on" fluorescent aptasensor based on fluorescence resonance energy transfer (FRET) and streptavidin-modified magnetic beads (MBs) for the sensitive and specific detection of A549 CTCs in lung cancer. The sensing strategy employs a biotinylated EGFR-targeting aptamer (Apt) labeled with FAM (donor) and a complementary S1 strand modified with BHQ-1 (acceptor). In the absence of target cells, the aptamer hybridizes with S1, bringing FAM and BHQ into close proximity, resulting in efficient fluorescence quenching ("off" state). Upon recognition of EGFR-overexpressing A549 cells, the aptamer undergoes a conformational change or strand displacement, releasing S1-BHQ and restoring FAM fluorescence ("on" state). Under optimized conditions, the aptasensor exhibited a linear response to A549 cell concentrations ranging from 50 to 5 × 105 cells per mL, with a detection limit as low as 34 cells per mL. The assay also demonstrated excellent selectivity against non-target cancer cells (SW620, HGC-27, MCF-7) and performed well in human serum samples, achieving a limit of detection of 105 (1.05 × 102) cells per mL. This FRET-based magnetic platform offers a simple and sensitive approach for CTC detection and shows potential as a tool for lung cancer liquid biopsy pending further validation with clinical patient samples.

View source

Similar papers

Open access Sep 2026

A target-activated AS1411 aptamer probe for in vivo and ex vivo imaging of nucleolin-overexpressing triple-negative breast cancer

Findings provide proof-of-concept support for further evaluation of activatable AS1411-based probes for molecular imaging of nucleolin-overexpressing TNBC and enable preferential, high-contrast fluorescence imaging in the tested MDA-MB-231 TNBC model across in vitro, in vivo, and ex vivo experiments.

Jun-Tao Tan, Zi-Xi Hu, Da Huang et al. · 0 citations
Nov 2026

Dual-aptamer-activated RCA-MOF synergistic platform for visual detection of leukemia-derived exosomes.

The sensitive, point-of-care detection of acute myeloid leukemia (AML)-derived exosomes is essential for non-invasive diagnosis and therapy monitoring, but remains technically challenging. Here we report a colorimetric biosensor based on a dual -aptamer-initiated catalytic cascade, where simultaneous recognition of exo...

Ying Shen, Yunlong Xiao, Lu Liu et al. · 0 citations
Open access Aug 2026

Cascade-coupled colorimetric-fluorescent dual-signal detection of EGFR-positive extracellular vesicles via bifunctional MOF@Pt nanozyme integrated with a CHA-CRISPR system.

Extracellular vesicle (EV)-based liquid biopsy holds great promise for glioma diagnosis, but its clinical translation remains hindered by inefficient isolation of disease-relevant EV subpopulations and insufficiently integrated signal validation. Herein, we develop a platform that integrates a bifunctional nanozyme sys...

Yan Wang, Bo-Ya Xu, Zehan Zeng et al. · 0 citations
Open access Sep 2026

Base-modified aptamer-DAPI probe for label-free detection of doxorubicin in dairy and serum samples

Doxorubicin is an important chemotherapeutic agent, making its sensitive detection essential for therapeutic monitoring and food safety assessment. Although DNA aptamers exhibit high affinity and specificity toward doxorubicin, the absence of well-defined structural motifs often hampers the development of rapid, labe...

Zi-Han Gao, Jia-Min Wu, Shi-Jing Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.